ReviewProblemy endokrinologii2025
[Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms].
Review in Problemy endokrinologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, the number of patients with diabetes has quadrupled over the past three decades. Every eleventh adult is currently diagnosed with diabetes mellitus, 90% of which are type 2 diabetes mellitus (DM2). Generally recognized complications of chronic hyperglycemia include micro- and macrovascular changes, damage to peripheral and/or autonomous nerve fibers. Scientists have also long discussed the relationship between an increase in the number of certain cancers and the presence of DM2. Based on the presence of common risk factors such as age, ethnicity, dietary habits and physical activity, many epidemiological and experimental studies are being conducted, which gradually contribute to understanding the relationship between these diseases. Taking into account the results of numerous studies, hyperglycemia, hyperinsulinemia and chronic inflammation, which are observed in DM 2, have a positive association with an increased risk of certain types of malignancies. In this article, the authors consider pathological changes in DM2 that potentiate the development of oncological diseases and epidemiological data reflecting the correlation between DM2 and the occurrence of malignant tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.